Y-mAbs Therapeutics, Inc.
YMAB
$8.53
$0.010.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -6.60% | -21.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.60% | -21.10% | |||
| Cost of Revenue | -9.63% | -61.73% | |||
| Gross Profit | -6.09% | -4.02% | |||
| SG&A Expenses | -10.02% | 7.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.26% | -14.05% | |||
| Operating Income | 0.27% | -28.79% | |||
| Income Before Tax | 37.74% | 31.17% | |||
| Income Tax Expenses | 40.00% | 100.66% | |||
| Earnings from Continuing Operations | 37.66% | 23.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.66% | 23.48% | |||
| EBIT | 0.27% | -28.79% | |||
| EBITDA | -0.05% | -30.20% | |||
| EPS Basic | 37.93% | 23.86% | |||
| Normalized Basic EPS | 24.53% | 28.88% | |||
| EPS Diluted | 37.93% | 24.26% | |||
| Normalized Diluted EPS | 24.53% | 28.88% | |||
| Average Basic Shares Outstanding | 0.47% | 0.51% | |||
| Average Diluted Shares Outstanding | 0.47% | 0.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||